By: Talking Nutrition Editors
The first 1,000 days of life represent a critical window of development, and the nutrition delivered during this time plays a foundational role in building lifelong health.3 Breastmilk remains the gold standard for promoting optimal growth and development and protecting against infections and nutritional deficiencies in infants.4 Lipids are an important source of energy in breastmilk and play a unique role in an infant’s health and development.
Breastmilk always provides the long-chain polyunsaturated fatty acids (LCPUFAs) ARA and DHA, suggesting the essential role of these lipids in infant nutrition. DHA and ARA are abundant in the tissues of the brain, eyes, heart, muscles, blood vessels, and immune cells. These LCPUFAs have been studied for their functional roles in growth, as well as in brain, vision and immune development and function over the last several decades.5-10
European regulations now mandate that all infant and follow-on formulas must contain DHA, while ARA is an optional ingredient.1 Despite this regulation, there are several important reasons why ARA should be added in combination with DHA to these formulas. Pediatric nutrition experts outline four key reasons why in a recent publication, summarized below.2
Worldwide, with few exceptions, breastmilk samples consistently show that concentrations of ARA are greater than DHA, with up to twice the amount of ARA. Moreover, ARA concentrations are less variable than those of DHA.11-12
An infant’s ability to synthesize ARA from the precursor fatty acid linoleic acid (LA) is influenced by gender, genetics, and the amount of LA in the diet. Conversion of LA to ARA is insufficient to maintain stable ARA concentrations in plasma and red blood cells. Thus, adding a supplemental source of ARA to infant and follow-on formulas may be necessary to more closely resemble reported concentrations of ARA in the breastfed infant.5,13 This is particularly relevant for infants who carry a genetic variation that negatively impacts the ability to convert LA to ARA. Affecting 30% of the general population in Europe, this results in a lower ARA status compared to infants without the genetic variant. Reduced ARA status may impact cognitive and immune system development, and the risk of developing allergies.12,14
Most studies on LCPUFAs demonstrate that certain developmental and physiologic outcomes are sensitive to the ratio of ARA to DHA. For example, functional outcomes in term infants were affected by the ratio of ARA:DHA in a large, randomized controlled trial that provided a fixed concentration of ARA (0.64% ARA of total fatty acids) in combination with varied concentrations of DHA (0.32, 0.64 or 0.96% DHA of total fatty acids) through the first 12 months of life.15 In long-term follow-up studies of this cohort, positive effects on certain measures of neurological development were observed at three to six years of age when ARA concentrations were at least equal to or greater than DHA (1:1 to 2:1 ARA:DHA ratios).8,9
An effective immune response includes both activation and resolution of inflammation. ARA supports an infant’s health through its effects on the immune system and the inflammatory response. Indeed, ARA is a major substrate in the synthesis of eicosanoids, which function to modulate inflammation. Additionally, studies show the balance between ARA and DHA is important. Feeding infants formula supplemented with DHA and ARA at ratios found in breastmilk positively impacts immune system markers.13-14 Conversely, providing high doses of omega-3 LCPUFAs (like DHA) without adding ARA results in an imbalance of the omega 6:omega 3 LCPUFA ratio in the diet, which reduces cell content of ARA. Scientists believe this may lead to an anti-inflammatory and immunosuppressive effect that is undesirable during the early postnatal period when the immune system is rapidly developing and acquiring essential functions.14,16
Based on their review of the evidence from research published over the last several decades, pediatric nutrition experts agree on the need to provide infants with a balanced supply of both DHA and ARA in order to support their LCPUFA status, as well as brain and immune system development and function.
dsm-firmenich is the global innovation leader for science-backed nutritional products and services. Our strategy, decisions and actions are all driven from a deep understanding of the science as well as the needs of our customers and consumers.
We believe in working collaboratively to deliver health benefit solutions that are as unique as the people that embrace your brand and products. The science behind the health and therapeutic benefits of our ingredients is core to our business. dsm-firmenich is an end-to-end partner with a comprehensive set of science-backed, high-quality products, custom premix solutions and expert services.
For more information about how dsm-firmenich can support you in the development of infant nutrition products for optimal early life nutrition, visit our knowledge hub.
25 January 2021
4 min read
Stay up-to-date on the latest science, events and market trends
Follow us on your favorite social networks.